Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Directly and reversibly blocks platelet P2Y12 receptors, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation. Its rapid onset and short offset are related to its intravenous administration and rapid plasma clearance.
Indications / reported uses
Adjunct to percutaneous coronary intervention (PCI) to reduce periprocedural myocardial infarction, repeat coronary revascularisation and stent thrombosis in patients not treated with an oral P2Y12 inhibitor and not receiving a glycoprotein IIb/IIIa inhibitor
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cangrelor PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cangrelor Permitted Daily Exposure (PDE) report (the Cangrelor PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cangrelor Occupational Exposure Limit (OEL) report (the Cangrelor OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.